A Solid-State Support for Separating Astatine-211 from Bismuth

David H. Woen; Cecilia Eiroa-Lledo; Andrew C. Akin; Nickolas H. Anderson; Kevin T. Bennett; Eva R. Birnbaum; Anastasia V. Blake; Mark Brugh; Elodie Dalodière; Eric F. Dorman; Maryline G. Ferrier; Donald K. Hamlin; Stosh A. Kozimor; Yawen Li; Laura M. Lilley; Veronika Mocko; Sara L. Thiemann; D. Scott Wilbur; Frankie D. White

doi:10.1021/acs.inorgchem.0c00221

A Solid-State Support for Separating Astatine-211 from Bismuth

David H. Woen, Cecilia Eiroa-Lledo, Andrew C. Akin, Nickolas H. Anderson, Kevin T. Bennett, Eva R. Birnbaum, Anastasia V. Blake, Mark Brugh, Elodie Dalodière, Eric F. Dorman, Maryline G. Ferrier, Donald K. Hamlin, Stosh A. Kozimor, Yawen Li, Laura M. Lilley, Veronika Mocko, Sara L. Thiemann, D. Scott Wilbur, Frankie D. White

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Increasing access to the short-lived α-emitting radionuclide astatine-211 (²¹¹At) has the potential to advance targeted α-therapeutic treatment of disease and to solve challenges facing the medical community. For example, there are numerous technical needs associated with advancing the use of ²¹¹At in targeted α-therapy, e.g., improving ²¹¹At chelates, developing more effective ²¹¹At targeting, and characterizing in vivo ²¹¹At behavior. There is an insufficient understanding of astatine chemistry to support these efforts. The chemistry of astatine is one of the least developed of all elements on the periodic table, owing to its limited supply and short half-life. Increasing access to ²¹¹At could help address these issues and advance understanding of ²¹¹At chemistry in general. We contribute here an extraction chromatographic processing method that simplifies ²¹¹At production in terms of purification. It utilizes the commercially available Pre-Filter resin to rapidly (<1.5 h) isolate ²¹¹At from irradiated bismuth targets (Bi decontamination factors ≥876 »000), in reasonable yield (68-55%) and in a form that is compatible for subsequent in vivo study. We are excited about the potential of this procedure to address ²¹¹At supply and processing/purification problems.

Original language	English
Pages (from-to)	6137-6146
Number of pages	10
Journal	Inorganic Chemistry
Volume	59
Issue number	9
DOIs	https://doi.org/10.1021/acs.inorgchem.0c00221
State	Published - May 4 2020
Externally published	Yes

Funding

This research was supported by the U.S. Department of Energy Isotope Program, managed by the Office of Science for Nuclear Physics. LANL is an affirmative action/equal opportunity employer managed by Triad National Security, LLC, for the National Nuclear Security Administration of the U.S. DOE under Contract 89233218CNA000001. We acknowledge support from LANL’s LDRD–DR (20180005DR). Postdoctoral support for N.H.A. was provided by the LANL Directors Fellowship.

Funders	Funder number
LANL’s LDRD	20180005DR
Office of Science for Nuclear Physics
U.S. Department of Energy	89233218CNA000001
National Nuclear Security Administration
Los Alamos National Laboratory

Access to Document

10.1021/acs.inorgchem.0c00221

Cite this

Woen, D. H., Eiroa-Lledo, C., Akin, A. C., Anderson, N. H., Bennett, K. T., Birnbaum, E. R., Blake, A. V., Brugh, M., Dalodière, E., Dorman, E. F., Ferrier, M. G., Hamlin, D. K., Kozimor, S. A., Li, Y., Lilley, L. M., Mocko, V., Thiemann, S. L., Wilbur, D. S., & White, F. D. (2020). A Solid-State Support for Separating Astatine-211 from Bismuth. Inorganic Chemistry, 59(9), 6137-6146. https://doi.org/10.1021/acs.inorgchem.0c00221

@article{042dabf86d5c405d8e91c2dc9cca251f,

title = "A Solid-State Support for Separating Astatine-211 from Bismuth",

abstract = "Increasing access to the short-lived α-emitting radionuclide astatine-211 (211At) has the potential to advance targeted α-therapeutic treatment of disease and to solve challenges facing the medical community. For example, there are numerous technical needs associated with advancing the use of 211At in targeted α-therapy, e.g., improving 211At chelates, developing more effective 211At targeting, and characterizing in vivo 211At behavior. There is an insufficient understanding of astatine chemistry to support these efforts. The chemistry of astatine is one of the least developed of all elements on the periodic table, owing to its limited supply and short half-life. Increasing access to 211At could help address these issues and advance understanding of 211At chemistry in general. We contribute here an extraction chromatographic processing method that simplifies 211At production in terms of purification. It utilizes the commercially available Pre-Filter resin to rapidly (<1.5 h) isolate 211At from irradiated bismuth targets (Bi decontamination factors ≥876 »000), in reasonable yield (68-55%) and in a form that is compatible for subsequent in vivo study. We are excited about the potential of this procedure to address 211At supply and processing/purification problems.",

author = "Woen, {David H.} and Cecilia Eiroa-Lledo and Akin, {Andrew C.} and Anderson, {Nickolas H.} and Bennett, {Kevin T.} and Birnbaum, {Eva R.} and Blake, {Anastasia V.} and Mark Brugh and Elodie Dalodi{\`e}re and Dorman, {Eric F.} and Ferrier, {Maryline G.} and Hamlin, {Donald K.} and Kozimor, {Stosh A.} and Yawen Li and Lilley, {Laura M.} and Veronika Mocko and Thiemann, {Sara L.} and Wilbur, {D. Scott} and White, {Frankie D.}",

note = "Publisher Copyright: {\textcopyright} 2020 American Chemical Society.",

year = "2020",

month = may,

day = "4",

doi = "10.1021/acs.inorgchem.0c00221",

language = "English",

volume = "59",

pages = "6137--6146",

journal = "Inorganic Chemistry",

issn = "0020-1669",

publisher = "American Chemical Society",

number = "9",

}

Woen, DH, Eiroa-Lledo, C, Akin, AC, Anderson, NH, Bennett, KT, Birnbaum, ER, Blake, AV, Brugh, M, Dalodière, E, Dorman, EF, Ferrier, MG, Hamlin, DK, Kozimor, SA, Li, Y, Lilley, LM, Mocko, V, Thiemann, SL, Wilbur, DS & White, FD 2020, 'A Solid-State Support for Separating Astatine-211 from Bismuth', Inorganic Chemistry, vol. 59, no. 9, pp. 6137-6146. https://doi.org/10.1021/acs.inorgchem.0c00221

TY - JOUR

T1 - A Solid-State Support for Separating Astatine-211 from Bismuth

AU - Woen, David H.

AU - Eiroa-Lledo, Cecilia

AU - Akin, Andrew C.

AU - Anderson, Nickolas H.

AU - Bennett, Kevin T.

AU - Birnbaum, Eva R.

AU - Blake, Anastasia V.

AU - Brugh, Mark

AU - Dalodière, Elodie

AU - Dorman, Eric F.

AU - Ferrier, Maryline G.

AU - Hamlin, Donald K.

AU - Kozimor, Stosh A.

AU - Li, Yawen

AU - Lilley, Laura M.

AU - Mocko, Veronika

AU - Thiemann, Sara L.

AU - Wilbur, D. Scott

AU - White, Frankie D.

PY - 2020/5/4

Y1 - 2020/5/4

N2 - Increasing access to the short-lived α-emitting radionuclide astatine-211 (211At) has the potential to advance targeted α-therapeutic treatment of disease and to solve challenges facing the medical community. For example, there are numerous technical needs associated with advancing the use of 211At in targeted α-therapy, e.g., improving 211At chelates, developing more effective 211At targeting, and characterizing in vivo 211At behavior. There is an insufficient understanding of astatine chemistry to support these efforts. The chemistry of astatine is one of the least developed of all elements on the periodic table, owing to its limited supply and short half-life. Increasing access to 211At could help address these issues and advance understanding of 211At chemistry in general. We contribute here an extraction chromatographic processing method that simplifies 211At production in terms of purification. It utilizes the commercially available Pre-Filter resin to rapidly (<1.5 h) isolate 211At from irradiated bismuth targets (Bi decontamination factors ≥876 »000), in reasonable yield (68-55%) and in a form that is compatible for subsequent in vivo study. We are excited about the potential of this procedure to address 211At supply and processing/purification problems.

AB - Increasing access to the short-lived α-emitting radionuclide astatine-211 (211At) has the potential to advance targeted α-therapeutic treatment of disease and to solve challenges facing the medical community. For example, there are numerous technical needs associated with advancing the use of 211At in targeted α-therapy, e.g., improving 211At chelates, developing more effective 211At targeting, and characterizing in vivo 211At behavior. There is an insufficient understanding of astatine chemistry to support these efforts. The chemistry of astatine is one of the least developed of all elements on the periodic table, owing to its limited supply and short half-life. Increasing access to 211At could help address these issues and advance understanding of 211At chemistry in general. We contribute here an extraction chromatographic processing method that simplifies 211At production in terms of purification. It utilizes the commercially available Pre-Filter resin to rapidly (<1.5 h) isolate 211At from irradiated bismuth targets (Bi decontamination factors ≥876 »000), in reasonable yield (68-55%) and in a form that is compatible for subsequent in vivo study. We are excited about the potential of this procedure to address 211At supply and processing/purification problems.

UR - http://www.scopus.com/inward/record.url?scp=85083890545&partnerID=8YFLogxK

U2 - 10.1021/acs.inorgchem.0c00221

DO - 10.1021/acs.inorgchem.0c00221

M3 - Article

C2 - 32302134

AN - SCOPUS:85083890545

SN - 0020-1669

VL - 59

SP - 6137

EP - 6146

JO - Inorganic Chemistry

JF - Inorganic Chemistry

IS - 9

ER -

A Solid-State Support for Separating Astatine-211 from Bismuth

Abstract

Funding

Access to Document

Other files and links

Fingerprint

Cite this